| Group A | Group B | Group C | Total | ||
| Localization | |||||
| Abdominal | 4 | 31 | 11 | 46 | |
| ORL | 1 | 8 | 2 | 11 | |
| Cervical | 2 | 2 | 4 | ||
| Bone | 3 | 3 | |||
| Other / combination | 9 | 3 | 10 | ||
| Results after COP | |||||
| > 25% response | 48 | 15 | 63 | ||
| < 25 % response | 2 | 1 | 3 | ||
| Results after CYM/CYVE | |||||
| CR | 37 | 14 | 51 | ||
| Residual mass | Viable tumour | 7 | |||
| Necrotic tissue | 6 | ||||
| Primary treatment outcome | |||||
| CR | 6 | 46 | 15 | 67 | |
| PR | 0 | ||||
| Resistant / progressive disease | 1 | 3 | 1 | 5 | |
| Death due to disease | 7 | 1 | 8 | ||
| Death due to toxicity | 2 | 1 | 3 | ||
| Relapse | |||||
| Local | 1 | 4 | 5 | ||
| BM | 2 | 2 | |||
| Local + BM ± CNS | 2 | 0 | |||
| BM + CNS | 0 | ||||
| CNS | 1 | 1 | |||
| Survival rate | |||||
| 2- year OS | 100% | 83.1% | 86.7% | ||
| 2-year EFS | 85.7% | 81.1% | 81.3% | ||